ACM
SUPN icon

Aquatic Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Aquatic Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,484
Closed -$992K – 1658
2025
Q2 		$992K Sell
31,484
-684
-2% -$21.9K 0.02% 647
2025
Q1 		$1.05M Buy
32,168
+31,342
+3,794% +$1.11M 0.03% 590
2024
Q4 		$29.9K Sell
826
-1,974
-71% -$69.5K ﹤0.01% 1216
2024
Q3 		$87.3K Buy
+2,800
New +$87.4K ﹤0.01% 939
2024
Q1 		– Sell
-4,700
Closed -$136K – 1624
2023
Q4 		$136K Buy
+4,700
New +$125K ﹤0.01% 940
2023
Q3 		– Sell
-19,600
Closed -$589K – 1633
2023
Q2 		$589K Buy
+19,600
New +$686K 0.03% 417
2022
Q3 		– Sell
-200
Closed -$6K – 1532
2022
Q2 		$6K Buy
+200
New +$5.73K ﹤0.01% 1035
2022
Q1 		– Sell
-100
Closed -$3K – 1503
2021
Q4 		$3K Buy
+100
New +$3.03K 0.01% 1018

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aquatic Capital Management's SUPN Position: Q3 2025 in Review

Aquatic Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 31,484 shares — an estimated $992K sold.

Aquatic Capital Management first reported a position in SUPN in Q4 2021 and held it in 8 quarters. The position peaked at $1.05M in Q1 2025. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Aquatic Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Aquatic Capital Management sold 31,484 Supernus Pharmaceuticals shares in Q3 2025, an estimated $992K.
  • Aquatic Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Aquatic Capital Management's Supernus Pharmaceuticals position peaked at $1.05M in Q1 2025.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Aquatic Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.